12 December 2023
12 December 2023
Latest draft of COP28 Global Stocktake dubbed "incoherent and dangerous" as language on fossil fuel phaseout is removed.
The FDA has approved Vertex/CRISPR’s Casgevy and bluebird bio’s Lyfgenia gene therapies for the red blood cell disorder.
Almirall will use etherna’s lipid nanoparticle (LNP)-based nucleic acid delivery platform to treat severe skin diseases, including non-melanoma skin cancer.
The authorisation is based on interim analysis data from the dMMR/MSI-H population in Part 1 of the RUBY trial.
Trends in sustainability and quality assurance were key themes discussed at the recent CPHI Europe 2023 meeting, although the data reveals a lack of implementation of sustainable solutions.
Pliant Therapeutics doubles down on enrolment for a Phase IIb IPF trial as other industry players also investigate new IPF therapies.
A study shared at ASH saw lupus and sclerosis patients make marked recoveries through CAR-T therapy initally targeted at blood cancers.
The funding will advance Hoba’s lead candidate HB-086 to a Phase I clinical trial for chemotherapy-induced neuropathic pain.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials.
Give your business an edge with our leading industry insights.
